Ixiaro

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Japanski encefalitis virus, inaktivirano (atenuiranih deformacije SA14-14-2 u vero stanicama)

Available from:

Valneva Austria GmbH

ATC code:

J07BA02

INN (International Name):

Japanese encephalitis vaccine (inactivated, adsorbed)

Therapeutic group:

cjepiva

Therapeutic area:

Encephalitis, Japanese; Immunization

Therapeutic indications:

Ixiaro je indiciran za aktivnu imunizaciju protiv japanskog encefalitisa kod odraslih, adolescenata, djece i dojenčadi starijih od dva mjeseca i starijih. Ixiaro moraju biti uzeti u obzir za uporabu u osoba pod rizikom zaraze kroz putovanja ili u toku svoje zanimanje,.

Product summary:

Revision: 17

Authorization status:

odobren

Authorization date:

2009-03-31

Patient Information leaflet

                                27
B. UPUTA O LIJEKU
28
UPUTA O LIJEKU: INFORMACIJE ZA KORISNIKA
IXIARO SUSPENZIJA ZA INJEKCIJU
cjepivo protiv japanskog encefalitisa (inaktivirano, adsorbirano)
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO VI ILI VAŠE DIJETE
PRIMITE OVO CJEPIVO JER SADRŽI VAMA VAŽNE
PODATKE.
•
Sačuvajte ovu uputu. Možda ćete je Vi i Vaše dijete trebati
ponovno pročitati.
•
Ako imate dodatnih pitanja, obratite se svom liječniku.
•
Ovo je cjepivo propisano samo za Vas i/ili Vaše dijete. Nemojte ga
davati drugima.
•
Ako Vi i/ili vaše dijete primijetite bilo koju nuspojavu, potrebno je
obavijestiti liječnika. To uključuje i
svaku moguću nuspojavu koja nije navedena u ovoj uputi. Pogledajte
dio 4.
ŠTO SE NALAZI U OVOJ UPUTI:
1.
Što je IXIARO i za što se koristi
2.
Što morate znati prije nego Vi i/ili Vaše dijete primite IXIARO
3.
Kako primjenjivati IXIARO
4.
Moguće nuspojave
5.
Kako čuvati IXIARO
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE IXIARO I ZA ŠTO SE KORISTI
IXIARO je cjepivo protiv virusa japanskog encefalitisa.
Cjepivo potiče tijelo da stvori vlastitu zaštitu (protutijela)
protiv ove bolesti.
IXIARO se koristi za sprječavanje infekcije virusom japanskog
encefalitisa (JEV). Ovaj se virus uglavnom
nalazi u Aziji i na ljude se prenosi ubodom komaraca koji su prethodno
uboli zaražene životinje (poput
svinje). Mnogi zaraženi ljudi razviju blage simptome ili ne razviju
nikakve simptome. U ljudi u kojih se
razvije teška bolest, japanski encefalitis (JE) obično počinje kao
bolest slična gripi, s vrućicom, zimicom,
umorom, glavoboljom, mučninom i povraćanjem. U ranoj fazi bolesti
također se javljaju smetenost i
uznemirenost.
IXIARO trebaju primati samo odrasli, adolescenti, djeca i dojenčad u
dobi od 2 mjeseca i više koji putuju u
zemlje u kojima je JE endemska bolest ili koji su zbog posla izloženi
riziku.
2.
ŠTO MORATE ZNATI PRIJE NEGO VI I/ILI VAŠE DIJETE POČNETE
PRIMJENJIVATI IXIARO
NEMOJTE PRIMJENJIVATI
IXIARO
:
•
Ako ste Vi i/ili Vaše dijete alergični (preosjetlji
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
IXIARO suspenzija za injekciju
Cjepivo protiv japanskog encefalitisa (inaktivirano, adsorbirano)
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
1 doza (0,5 ml) cjepiva IXIARO sadrži:
virus japanskog encefalitisa soj SA
14
-14-2 (inaktiviran)
1,2
6 AU
3
,
što odgovara vrijednosti ≤ 460 ng ED50
1
proizveden na Vero stanicama
2
adsorbiran na aluminijev hidroksid, hidratizirani (približno 0,25
miligrama Al
3+
)
3
antigen jedinica
Pomoćne tvari s poznatim učinkom:
Ovaj lijek sadrži kalij, manje od 1 mmol (39 mg) po jednoj dozi od
0,5 ml, tj. zanemarive količine kalija te
manje od 1 mmol (23 mg) natrija po jednoj dozi od 0,5 ml, tj.
zanemarive količine natrija. Ovaj lijek može
sadržavati ostatake natrijeva metabisulfita koji su ispod granice
detekcije.
Fiziološka otopina s fosfatnim puferom 0,0067 M (u PO
4
) ima sljedeći sastav fiziološke otopine:
NaCl – 9mg/mL
KH
2
PO
4
– 0,144 mg/mL
Na
2
HPO
4
– 0,795 mg/mL
Za cjeloviti popis pomoćnih tvari, vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Suspenzija za injekciju.
Bistra tekućina s bijelim talogom.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
IXIARO je indiciran za aktivnu imunizaciju protiv japanskog
encefalitisa u odraslih, adolescenata, djece i
dojenčadi u dobi od 2 mjeseca i starije.
Primjenu cjepiva IXIARO treba razmotriti u osoba izloženih riziku
zbog putovanja ili obavljanja poslovnih
aktivnosti.
4.2
DOZIRANJE I NAČIN PRIMJENE
Doziranje
ODRASLI (18 DO
≤ 65 GODINA)
Primarno cijepljenje se sastoji od dvije odvojene doze, svaka od 0,5
ml, koje se primaju prema sljedećem
konvencionalnom rasporedu:
Prva doza na nulti (0.) dan.
Druga doza: 28 dana nakon prve doze.
Brzi raspored
Osobe u dobi od 18 do ≤ 65 godina mogu primiti cjepivo prema brzom
rasporedu kako slijedi:
3
Prva doza na nulti (0.) dan.
Druga doza: 7 dana nakon prve doze.
Bez obzira na primijenjeni raspored, primarna imunizacija trebala bi
se dovršiti najmanje jedan tjedan prije
potencijalnog izlaganja virusu japanskog encefalit
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 12-04-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 12-04-2021
Public Assessment Report Public Assessment Report Bulgarian 15-03-2019
Patient Information leaflet Patient Information leaflet Spanish 12-04-2021
Public Assessment Report Public Assessment Report Spanish 15-03-2019
Patient Information leaflet Patient Information leaflet Czech 12-04-2021
Public Assessment Report Public Assessment Report Czech 15-03-2019
Patient Information leaflet Patient Information leaflet Danish 12-04-2021
Public Assessment Report Public Assessment Report Danish 15-03-2019
Patient Information leaflet Patient Information leaflet German 12-04-2021
Public Assessment Report Public Assessment Report German 15-03-2019
Patient Information leaflet Patient Information leaflet Estonian 12-04-2021
Public Assessment Report Public Assessment Report Estonian 15-03-2019
Patient Information leaflet Patient Information leaflet Greek 12-04-2021
Public Assessment Report Public Assessment Report Greek 15-03-2019
Patient Information leaflet Patient Information leaflet English 12-04-2021
Public Assessment Report Public Assessment Report English 15-03-2019
Patient Information leaflet Patient Information leaflet French 12-04-2021
Public Assessment Report Public Assessment Report French 15-03-2019
Patient Information leaflet Patient Information leaflet Italian 12-04-2021
Public Assessment Report Public Assessment Report Italian 15-03-2019
Patient Information leaflet Patient Information leaflet Latvian 12-04-2021
Public Assessment Report Public Assessment Report Latvian 15-03-2019
Patient Information leaflet Patient Information leaflet Lithuanian 12-04-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 12-04-2021
Public Assessment Report Public Assessment Report Lithuanian 15-03-2019
Patient Information leaflet Patient Information leaflet Hungarian 12-04-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 12-04-2021
Public Assessment Report Public Assessment Report Hungarian 15-03-2019
Patient Information leaflet Patient Information leaflet Maltese 12-04-2021
Public Assessment Report Public Assessment Report Maltese 15-03-2019
Patient Information leaflet Patient Information leaflet Dutch 12-04-2021
Public Assessment Report Public Assessment Report Dutch 15-03-2019
Patient Information leaflet Patient Information leaflet Polish 12-04-2021
Public Assessment Report Public Assessment Report Polish 15-03-2019
Patient Information leaflet Patient Information leaflet Portuguese 12-04-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 12-04-2021
Public Assessment Report Public Assessment Report Portuguese 15-03-2019
Patient Information leaflet Patient Information leaflet Romanian 12-04-2021
Public Assessment Report Public Assessment Report Romanian 15-03-2019
Patient Information leaflet Patient Information leaflet Slovak 12-04-2021
Public Assessment Report Public Assessment Report Slovak 15-03-2019
Patient Information leaflet Patient Information leaflet Slovenian 12-04-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 12-04-2021
Public Assessment Report Public Assessment Report Slovenian 15-03-2019
Patient Information leaflet Patient Information leaflet Finnish 12-04-2021
Public Assessment Report Public Assessment Report Finnish 15-03-2019
Patient Information leaflet Patient Information leaflet Swedish 12-04-2021
Public Assessment Report Public Assessment Report Swedish 15-03-2019
Patient Information leaflet Patient Information leaflet Norwegian 12-04-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 12-04-2021
Patient Information leaflet Patient Information leaflet Icelandic 12-04-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 12-04-2021

View documents history